Sue Siegel is a member of the board of directors of Pacific Biosciences, according to a press release from Mohr Davidow Ventures last month. Siegel, who used to be president and director of Affymetrix, recently joined MDV as a partner (see In Sequence 04/03/07). Pacific Biosciences, based in Menlo Park, Calif., is developing a new DNA sequencing technology with funding from MDV and others (see Short Reads in this issue).
Helicos BioSciences disclosed several personnel changes in a filing with the US Securities and Exchange Commission last week:
Steve Lombardi was promoted to executive vice president and chief operating officer in February. Lombardi joined the company in June 2006 as senior vice president of marketing. Prior to joining Helicos, he was senior vice president at Affymetrix and held several business and executive roles at Applied Biosystems, where he led the formation of the company’s DNA sequencing and genetic analysis business.
In addition, Claire Fraser-Liggett and Theo Melas-Kyriazi both joined the company’s board of directors in March. Fraser served as president and director of the Institute for Genomic Research from 1998 until earlier this month, when she resigned to lead a new genomics institute at the University of Maryland School of Medicine in Baltimore (see In Sequence 04/10/07). Fraser also serves on the board of trustees of Rensselaer Polytechnic Institute and on the board of directors of Becton, Dickinson. Melas-Kyriazi is currently chief financial officer of Levitronix, a developer of magnetically-levitated bearingless motor technology. He previously served as chief financial officer of Thermo Electron.
Jonathan Rothberg has voluntarily resigned as a director of CuraGen on April 13, the company said in a filing with the US Securities and Exchange Commission last week. Rothberg founded the company and previously served as CEO, president, and chairman of the board. He stepped down as CEO in 2005.
Rothberg also founded CuraGen subsidiary 454 Life Sciences, and currently serves as chairman of 454’s board. Earlier this month, CuraGen signed a definitive agreement to sell 454 to Roche (see In Sequence 04/03/07).